At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
bupropion hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation
In Brief
A Phase 2 clinical trial evaluating bupropion hydrochloride and placebo for Bladder Cancer and 10 related conditions. Completed, enrolled 95 participants across 1 site.
Detailed Summary
RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking. PURPOSE: This randomized phase II trial is studying how well bupropion works in helping adults stop smoking.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedSep 2007
Primary CompletionMay 2008
Study CompletionJul 2015
TodayJul 2026
First PostedSep 24, 2007
Enrollment StartJan 1, 2006
Primary CompletionMay 1, 2008
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.8 years ago
Interventions
bupropion hydrochloridedrug
Given orally
placeboother
Given orally